Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bi-(AID-1-T)
- Development stage
- Preclinical
- Lead developer
- Burdenko National Medical Research Center of Neurosurgery
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
bi-(AID-1-T) is a bi-modular G-quadruplex (GQ) DNA aptamer designed by the covalent conjugation of two three-quartet AID-1-T molecules via a three-thymidine (TTT) linker. It exhibits anti-proliferative and cytostatic activity against high-grade glioma (including glioblastoma multiforme) by targeting the cytoplasmic form of poly [ADP-ribose] polymerase 1 (PARP1). While bi-(AID-1-T) monotherapy has been shown to inhibit glioma cell proliferation, it can paradoxically stimulate the migration of recurrent tumor cells. However, when combined with ionizing radiation, bi-(AID-1-T) acts synergistically to significantly reduce both cell proliferation and migration, suppressing radiation-induced migratory enhancement.
- Other names
- bi-AID-1-Tbi-AID1-Tbi-AID 1-Tbi(AID-1-T)
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on bi-(AID-1-T).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bi-(AID-1-T).